AAAAAA
Results:
1-19
|
Results: 19
Authors:
JUNGNELIUS U
RINGBORG U
AAMDAL S
MATTSSON J
STIERNER U
INGVAR C
MALMSTROM P
ANDERSSON R
KARLSSON M
WILLMAN K
WIST E
BJELKENGREN G
WESTBERG R
Citation: U. Jungnelius et al., DACARBAZINE-VINDESINE VERSUS DACARBAZINE-VINDESINE-CISPLATIN IN DISSEMINATED MALIGNANT-MELANOMA - A RANDOMIZED PHASE-III TRIAL, European journal of cancer, 34(9), 1998, pp. 1368-1374
Authors:
SEMB KA
AAMDAL S
METTE E
INGVAR C
GULLAKSEN N
OSMUNDSEN K
Citation: Ka. Semb et al., ZILASCORB(H-2), A LOW-TOXICITY PROTEIN-SYNTHESIS INHIBITOR THAT EXHIBITS SIGNS OF ANTICANCER ACTIVITY IN MALIGNANT-MELANOMA, Anti-cancer drugs, 9(9), 1998, pp. 797-802
Authors:
FAYE R
AAMDAL S
HOIFODT HK
JACOBSEN E
KVALHEIM G
SKOVLUND E
FODSTAD O
Citation: R. Faye et al., DETECTION OF OCCULT TUMOR-CELLS IN PERIPHERAL-BLOOD AND BONE-MARROW IN MELANOMA PATIENTS, AND HAS IT PROGNOSTIC-SIGNIFICANCE, Annals of oncology, 9, 1998, pp. 569-569
Authors:
AAMDAL S
DOMBERNOWSKY P
WANDERS J
CAPRIATI A
LUND B
Citation: S. Aamdal et al., A PHASE-I STUDY OF THE NOVEL ANTRACYCLINE ANALOG MEN-10755 BMS-195615(NAA) IN PATIENTS (PTS) WITH A SOLID TUMOR - PRELIMINARY-RESULTS/, Annals of oncology, 9, 1998, pp. 656-656
Authors:
SEMB KA
AAMDAL S
OIAN P
Citation: Ka. Semb et al., A CAPILLARY PROTEIN LEAK SYNDROME EXPLAINS FLUID RETENTION FOLLOWING TREATMENT WITH DOCETAXEL BUT NOT INTERLEUKIN-2, Annals of oncology, 9, 1998, pp. 662-662
Authors:
SEMB KA
AAMDAL S
OIAN P
Citation: Ka. Semb et al., CAPILLARY PROTEIN LEAK SYNDROME APPEARS TO EXPLAIN FLUID RETENTION INCANCER-PATIENTS WHO RECEIVE DOCETAXEL TREATMENT, Journal of clinical oncology, 16(10), 1998, pp. 3426-3432
ZILASCORB(H-2), A NEW REVERSIBLE PROTEIN-SYNTHESIS INHIBITOR - CLINICAL-STUDY OF AN ORAL PREPARATION
Authors:
SEMB KA
FODSTAD O
KLEM B
BIBOW K
OSMUNDSEN K
AAMDAL S
Citation: Ka. Semb et al., ZILASCORB(H-2), A NEW REVERSIBLE PROTEIN-SYNTHESIS INHIBITOR - CLINICAL-STUDY OF AN ORAL PREPARATION, Anti-cancer drugs, 8(3), 1997, pp. 296-303
Authors:
AAMDAL S
BRUNTSCH U
KERGER J
VERWEIJ J
HUININK WT
WANDERS J
RASTOGI R
FRANKLIN HR
KAYE SB
Citation: S. Aamdal et al., ZENIPLATIN IN ADVANCED MALIGNANT-MELANOMA AND RENAL-CANCER - PHASE-IISTUDIES WITH UNEXPECTED NEPHROTOXICITY, Cancer chemotherapy and pharmacology, 40(5), 1997, pp. 439-443
Authors:
FODSTAD O
OVERLI GET
FORUS A
RYE PD
BEISKE K
AAMDAL S
HOIFODT HK
Citation: O. Fodstad et al., IMPROVED IMMUNOMAGNETIC METHOD FOR DETECTION AND CHARACTERIZATION OF CANCER-CELLS IN BLOOD AND BONE-MARROW, Experimental hematology, 25(8), 1997, pp. 615-615
Authors:
MCLEOD HL
GRAHAM MA
AAMDAL S
SETANOIANS A
GROOT Y
LUND B
Citation: Hl. Mcleod et al., PHASE-I PHARMACOKINETICS AND LIMITED SAMPLING STRATEGIES FOR THE BIOREDUCTIVE ALKYLATING DRUG E09, European journal of cancer, 32A(9), 1996, pp. 1518-1522
Authors:
KARLSSON M
JUNGNELIUS U
AAMDAL S
BOERYD B
CARSTENSEN J
KAGEDAL B
WESTBERG R
WINGREN S
Citation: M. Karlsson et al., CORRELATION OF DNA-PLOIDY AND S-PHASE FRACTION WITH CHEMOTHERAPEUTIC RESPONSE AND SURVIVAL IN A RANDOMIZED STUDY OF DISSEMINATED MALIGNANT-MELANOMA, International journal of cancer, 65(1), 1996, pp. 1-5
Authors:
MCLEOD HL
MURRAY LS
WANDERS J
SETANOIANS A
GRAHAM MA
PAVLIDIS N
HEINRICH B
HUININK WWT
WAGENER DJT
AAMDAL S
VERWEIJ J
Citation: Hl. Mcleod et al., MULTICENTER PHASE-II PHARMACOLOGICAL EVALUATION OF RHIZOXIN, British Journal of Cancer, 74(12), 1996, pp. 1944-1948
Authors:
HANAUSKE AR
CATIMEL G
AAMDAL S
HUININK WT
PARIDAENS R
PAVLIDIS N
KAYE SB
TEVELDE A
WANDERS J
VERWEIJ J
Citation: Ar. Hanauske et al., PHASE-II CLINICAL-TRIALS WITH RHIZOXIN IN BREAST-CANCER AND MELANOMA, British Journal of Cancer, 73(3), 1996, pp. 397-399
Authors:
VERWEIJ J
CATIMEL G
SULKES A
STERNBERG C
WOLFF I
AAMDAL S
VANHOESEL Q
Citation: J. Verweij et al., PHASE-II STUDIES OF DOCETAXEL IN THE TREATMENT OF VARIOUS SOLID TUMORS, European journal of cancer, 31A, 1995, pp. 21-24
Authors:
FOSSA SD
AAMDAL S
NAUME B
GALLATI H
Citation: Sd. Fossa et al., SERUM LEVELS OF CYTOKINES AND SOLUBLE CYTOKINE RECEPTORS IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA OR MALIGNANT-MELANOMA RECEIVING IL-2 INTERFERON-ALPHA COMBINATION THERAPY, Acta oncologica, 34(5), 1995, pp. 599-603
Authors:
VERWEIJ J
AAMDAL S
SCHELLENS J
KOIER I
LUND B
Citation: J. Verweij et al., CLINICAL-STUDIES WITH EO9, A NEW INDOLOQUINONE BIOREDUCTIVE ALKYLATING CYTOTOXIC AGENT, Oncology research, 6(10-11), 1994, pp. 519-523
Authors:
AAMDAL S
WOLFF I
KAPLAN S
PARIDAENS R
KERGER J
SCHACHTER J
WANDERS J
FRANKLIN HR
VERWEIJ J
Citation: S. Aamdal et al., DOCETAXEL (TAXOTERE) IN ADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY OF THE EORTC EARLY CLINICAL-TRIALS GROUP, European journal of cancer, 30A(8), 1994, pp. 1061-1064
Authors:
SESSA C
AAMDAL S
WOLFF I
EPPELBAUM R
SMYTH JF
SULKES A
HUININK WTB
VERMORKEN J
WANDERS J
FRANKLIN H
VERWEIJ J
Citation: C. Sessa et al., GEMCITABINE IN PATIENTS WITH ADVANCED MALIGNANT-MELANOMA OR GASTRIC-CANCER - PHASE-II STUDIES OF THE EORTC EARLY CLINICAL-TRIALS GROUP, Annals of oncology, 5(5), 1994, pp. 471-472
Authors:
LUNDBY B
BERG KJ
LIEN HH
AAMDAL S
Citation: B. Lundby et al., A DOUBLE-BLIND-STUDY TO EVALUATE THE TOLERABILITY OF GADODIAMIDE INJECTION AND ITS EFFECT ON RENAL-FUNCTION IN PATIENTS UNDERGOING CEREBRALMAGNETIC-RESONANCE-IMAGING, British journal of radiology, 66(790), 1993, pp. 871-876
Risultati:
1-19
|